Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

By sjmartinez • January 26, 2023

Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, Pierce KJ, Mutka SC, Wainberg ZA. Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. Br J Cancer. 2023 Jan 25. doi: 10.1038/s41416-023-02161-w. Epub ahead of print. Erratum for: Br J Cancer. 2023 Jan;128(1):30-41. PMID: 36697966.

Tags: Hematology/Oncology, Publications

Paraneoplastic Trichomegaly as a Harbinger of Metastatic Renal Cell Carcinoma: A Case Report

Reichl A, Callahan R. Paraneoplastic Trichomegaly as a Harbinger of Metastatic Renal Cell Carcinoma: A Case Report. Cureus. 2025 May 6;17(5):e83550. doi: 10.7759/cureus.83550. PMID: 40476135;[...]

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Lucas PC, Gupta N, Li[...]

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Riess JW, de Langen AJ, Ponce S, Goldberg SB, Piotrowska Z, Goldman JW, Le X, Cho BC, Yoneshima Y, Ambrose H, Cavazzina R, Tang KH,[...]